Shopping Cart
- Remove All
- Your shopping cart is currently empty
CDK5-IN-4 (compound 4), a potent type-II multikinase inhibitor, targets CDK5 with an IC 50 of 9.8 μM. Additionally, it inhibits GSK-3α, GSK-3β, CDK9, and CDK2, demonstrating IC 50 values of 0.98, 4.00, 1.76, and 6.24 μM, respectively. This compound is applicable in glioblastoma research.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | CDK5-IN-4 (compound 4), a potent type-II multikinase inhibitor, targets CDK5 with an IC 50 of 9.8 μM. Additionally, it inhibits GSK-3α, GSK-3β, CDK9, and CDK2, demonstrating IC 50 values of 0.98, 4.00, 1.76, and 6.24 μM, respectively. This compound is applicable in glioblastoma research. |
Targets&IC50 | GSK-3β:4.00 ± 1.3 μM, GSK-3α:0.98 ± 0.0 μM, CDK2:6.24 ± 2.8 μM, CDK9:1.76 ± 0.3 μM, CDK5:9.8 ± 2.29 μM |
Molecular Weight | 449.48 |
Formula | C24H24FN5O3 |
Cas No. | 1212711-91-5 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.